RxDoctor Payments Data

Raghavendra Charan Makam, MD

Cardiovascular Disease · Vero Beach, FLNPI 1235378217

Payments from drug & device makers

$109,755in general payments, 2019–2025

Across 166 payments — averaging $661.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lexicon Pharmaceuticals, Inc.$57K
  • Boehringer Ingelheim$23K
  • Lilly USA, LLC$13K
  • Pfizer$7K
  • Bayer$7K
  • Abiomed$1K
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$91,11083%
  • Travel & lodging$12,55711%
  • Food & beverage$5,7605%
  • Education$3280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,755 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$206,326
Medicare patients
1,854
Services billed
4,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis88$2,011,595
JardianceEmpagliflozin248$332,357
EliquisApixaban166$208,822
EntrestoSacubitril/Valsartan92$144,540
CamzyosMavacamten15$111,980
VerquvoVericiguat41$59,291
FarxigaDapagliflozin Propanediol46$58,148
Repatha SureclickEvolocumab28$32,358
XareltoRivaroxaban26$25,818
Metoprolol Succinate302$4,369
Rosuvastatin Calcium225$3,245
Potassium Chloride24$2,654
Midodrine Hcl14$2,435
Ezetimibe46$1,748
Valsartan54$1,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$7,080$2,220,417254 claims
Boehringer IngelheimJardiance$22,864$332,357248 claims
NovartisEntresto$25$144,54092 claims
E.r. Squibb & Sons, L.L.C.Camzyos$16$111,98015 claims
MerckVerquvo$17$59,29141 claims
AstraZenecaFarxiga$228$58,14846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →